--- title: "Emergent BioSolutions authorizes repurchase of up to $50 million of stock" url: "https://aibio.space/news/emergent-biosolutions-authorizes-repurchase-up-50-million-stock/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-03-31" section: "Financings" tickers: "NYSE:EBS" source: "https://www.sec.gov/Archives/edgar/data/1367644/000136764425000087/ebs-20250331.htm" summary: "The board approved the Share Repurchase Program on March 31, 2025. The 8-K says the full terms are in a press release attached as Exhibit 99.1, and the 8-K" --- By the aibio.space news desk. Sources - [Emergent BioSolutions Inc. 8-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000087/ebs-20250331.htm) - [Emergent BioSolutions Inc. 10-K (2025-03-04): business](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000021/ebs-20241231.htm) [EBS](https://aibio.space/companies/emergent-biosolutions/) 2025-03-31 # Emergent BioSolutions authorizes repurchase of up to $50 million of stock Tickers [EBS](https://aibio.space/companies/emergent-biosolutions/) The board approved the Share Repurchase Program on March 31, 2025. The 8-K says the full terms are in a press release attached as Exhibit 99.1, and the 8-K body gives none of them. ## Key facts - **Company**: Emergent BioSolutions Inc. (NYSE: EBS) - **News type**: Financings - **Primary source**: [Emergent BioSolutions Inc. 8-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000087/ebs-20250331.htm) *A distant skyline over open water. Photo: Matt Bango, CC0, via StockSnap. The picture shows the field, not the companies named.* ## What the 8-K says Emergent BioSolutions Inc. (NYSE: [EBS](https://aibio.space/companies/emergent-biosolutions/)) said on March 31, 2025 that its Board of Directors had authorized the repurchase of up to $50 million of the company's common stock. The company calls the plan the Share Repurchase Program. It disclosed the step in a current report on Form 8-K filed under Item 8.01, Other Events. The 8-K says the full text of the press release is attached as Exhibit 99.1 and incorporated by reference. The body of the 8-K gives no further terms, so timing, method and duration are not stated in it. An authorization permits buybacks; it does not show that any shares have been bought. The 8-K names no underwriter, placement agent or financial advisor for the program. The filing was signed by Richard S. Lindahl, Executive Vice President, Chief Financial Officer and Treasurer. The company's principal executive offices are at 300 Professional Drive in Gaithersburg, Maryland. ## What the company sells The company describes itself as a global life sciences company focused on preparedness and response solutions for public health threats. Its business covers chemical, biological, radiological, nuclear and explosives threats, emerging infectious diseases, emerging health crises, and acute, emergency and community care. The annual report says it had 10 products it was actively developing or marketing as of December 31, 2024, and that those products make up a substantial portion of revenue. Its three reportable segments are a Commercial Product Segment, built around NARCAN Nasal Spray; an MCM Products Segment, covering anthrax and smallpox medical countermeasures; and a Services Segment, which provides bioservices such as drug substance manufacturing, fill and finish, packaging and development work. NARCAN is sold over the counter at retail pharmacies and online, and also by prescription to health departments, law enforcement agencies, community organizations and federal agencies. The U.S. government is the company's largest customer, according to the annual report. Its Government MCM business focuses mainly on procurement of countermeasures by domestic and international government customers, so government demand is central to that segment. ## Divestitures and milestone money In May 2023 the company sold its travel health business to Bavarian Nordic, including the licensed typhoid vaccine Vivotif, the cholera vaccine Vaxchora, the chikungunya vaccine candidate CHIKV VLP, a manufacturing site in Bern, Switzerland, and some San Diego facilities. Bavarian Nordic may pay milestones tied to CHIKV VLP and earn-out payments of up to $30.0 million based on net sales of Vaxchora and Vivotif in calendar 2026. The company says it has achieved all four development milestones under that deal. The first, $10.0 million, followed a European Medicines Agency validation in July 2024. The second, $20.0 million, followed FDA acceptance with Priority Review in August 2024. The third, $30.0 million, followed FDA approval on February 14, 2025 for people 12 years and older. The fourth, $20.0 million, followed European Commission approval on February 28, 2025. The first and second payments were received in 2024, so $30.0 million of up to $80.0 million in total milestones had been received as of December 31, 2024. It expects the third and fourth payments in the first half of 2025. These are one-time receipts from a sale, not operating sales. The company also sold its worldwide rights to RSDL to SERB Pharmaceuticals, through its subsidiary BTG International Inc., under an agreement entered into on July 31, 2024. The annual report says a transition services agreement with Bavarian Nordic was substantially completed in the third quarter of 2024, with some services continuing at year-end. ## What the 8-K leaves out The 8-K gives no cash balance, no net loss and no share count, and it does not say how much of the $50 million the company expects to spend. It also does not explain how the program would be funded, given the divestitures and milestone receipts described above. The authorization is a board decision announced in one sentence of the 8-K. Any purchases, their size and their timing will appear only in later filings, if the company makes them. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story EBS Emergent BioSolutions Inc. NYSE ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/emergent-biosolutions-authorizes-repurchase-up-50-million-stock/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Emergent BioSolutions authorizes repurchase of up to $50 million of stock", 2025-03-31, https://aibio.space/news/emergent-biosolutions-authorizes-repurchase-up-50-million-stock/